ACTIVE PATHOGEN DETECTION UTILIZING CUTTING EDGE GENOMIC TECHNOLOGY
Infectious diseases can present unique challenges for physicians in both the accurate identification of the disease, as well as the targeted treatment. At CSI, we are leveraging proprietary genomic sample preparation techniques and bioinformatic data analyses to identify trace active pathogenic signals in clinical specimens to help simplify this problem.
Detect All Active Pathogens With One Test — CSI-Dx™
The CSI-Dx™ test directly isolates and identifies any active bacterial, viral, or eukaryotic pathogenic microorganisms present in a sample. CSI-Dx™ detects a pathogen’s RNA to identify active infections, and is being clinically validated to identify both acute infection cases as well as chronic infection flare-up.
Benefits Of CSI-DX™
- Multiple Sample Matrices – CSI-Dx™ is currently analytically validated to detect trace pathogenic activity in urine and is being clinically validated in both blood and synovial fluid sample matrices.
- Untargeted – CSI-Dx™ is unlike traditional diagnostics in that it is not limited by targeted primers that can only identify single pathogenic species. The CSI-Dx™test utilizes comprehensive microbial RNA sequence data to identify and analyze the activity of all pathogens in a sample.
- Active Pathogen Identification – CSI-Dx™ targets transcriptionally active RNA from living pathogens, ignoring false-positive signals that can be caused by “dead” or “naked” DNA.
- Highly Sensitive, with a low Limit of Detection – CSI-Dx™ yields high analytical sensitivity and can detect low levels of pathogenic signal, down to 3 cells/mL, in human clinical specimens.
- Sample to Result – CSI-Dx™ gets patients and physicians their results more quickly than traditional diagnostics.
- Ongoing Research & Development – CSI-Dx™is currently undergoing active R&D in an effort to produce additional functional diagnostic information for patients. Specifically, CSI-Dx™is capable of informing clinicians of antibiotic resistance genes, and pro-inflammatory biomarkers, that can further inform physician care of challenging infectious disease diagnosis.